וגיפם 10 מקג ישראל - עברית - Ministry of Health

וגיפם 10 מקג

novo nordisk ltd., israel - estradiol hemihydrate - טבליות מצופות פילם - estradiol hemihydrate 10 mcg - estradiol - estradiol - treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women.

נובופם ישראל - עברית - Ministry of Health

נובופם

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.

אביאנה ישראל - עברית - Ministry of Health

אביאנה

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 0.5 mg; norethisterone acetate 0.1 mg - estradiol, combinations - estradiol, combinations - eviana is indicated for women who have a uterus for the: treatment of moderate to severe vasomotor symptoms associated with menopause. prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.

נורדיטרופין 15 מג ישראל - עברית - Ministry of Health

נורדיטרופין 15 מג

novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 10 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.

נורדיטרופין 10 מג ישראל - עברית - Ministry of Health

נורדיטרופין 10 מג

novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 10 mg / 1.5 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.

נורדיטרופין 5 מג ישראל - עברית - Ministry of Health

נורדיטרופין 5 מג

novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 3.3 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.

גלוקגן היפוקיט 1 מג ישראל - עברית - Ministry of Health

גלוקגן היפוקיט 1 מג

novo nordisk ltd., israel - glucagon as hydrochloride - אבקה וממס להכנת תמיסה להזרקה - glucagon as hydrochloride 1 mg - glucagon - glucagon - treatment of severe hypoglycaemia reactions which may occur in the management of insulin treated persons with diabetes.

פוסידין ישראל - עברית - Ministry of Health

פוסידין

dexcel ltd, israel - sodium fusidate - טבליה - sodium fusidate 250 mg - fusidic acid - fusidic acid - for the treatment of infections caused by staphylococcus.

אוונקס תמיסה להזרקה ישראל - עברית - Ministry of Health

אוונקס תמיסה להזרקה

medison pharma ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

פרוטופיק % 0.03 ישראל - עברית - Ministry of Health

פרוטופיק % 0.03

dexcel ltd, israel - tacrolimus - משחה - tacrolimus 0.03 %w/w - tacrolimus - tacrolimus - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).